CRA-026440 hydrochloride 是一种有效的广谱HDAC(HDAC) 抑制剂。作用于HDAC1,HDAC2,HDAC3,HDAC6,HDAC8和HDAC10的Ki分别为 4 nM,14 nM,11 nM,15 nM,7 nM 和 20 nM。CRA-026440 hydrochloride 具有抗肿瘤和抗血管生成活性。
生物活性 | CRA-026440 hydrochloride is a potent, broad-spectrumHDAC(HDAC) inhibitor. TheKivalues against recombinantHDACisoenzymesHDAC1,HDAC2,HDAC3,HDAC6,HDAC8, andHDAC10are 4 nM, 14 nM, 11 nM, 15 nM, 7 nM, and 20 nM respectively. CRA-026440 hydrochloride shows antitumor and antiangiogenic activities[1]. |
IC50& Target[1] | HDAC1 4 nM (IC50) | HDAC2 14 nM (IC50) | HDAC3/SMRT 11 nM (IC50) | HDAC6 15 nM (IC50) | HDAC8 7 nM (IC50) | HDAC10 20 nM (IC50) |
|
体外研究 (In Vitro) | CRA-026440 hydrochloride 对 HUVEC 内皮细胞具有抗增殖作用,GI50值为 1.41 μM[1]。 CRA-026440 hydrochloride(0.1-10 μM;18 小时)导致乙酰化组蛋白和乙酰化微管蛋白的积累,从而抑制肿瘤细胞生长并诱导细胞凋亡[1]。 CRA-026440 hydrochloride(0.1-10 μM;5 天)以剂量依赖性方式抑制离体血管生成[1]。
Western Blot Analysis[1] Cell Line: | HCT116 cells | Concentration: | 0.1 μM, 0.5 μM, 1 μM, 5 μM, 10 μM | Incubation Time: | 18 hours | Result: | Resulted in the accumulation of both acetylated histones and acetylated tubulin. Induced expression of the cyclin-dependent kinase inhibitor p21Cip1/WAF1. |
|
体内研究 (In Vivo) | CRA-026440 hydrochloride(100 mg/kg;静脉注射;每天;连续三天)导致携带 HCT116 或 U937 人肿瘤异种移植物的小鼠肿瘤生长显着减少[1]。
Animal Model: | HCT-116 tumor-bearing nude mice[1] | Dosage: | 100 mg/kg | Administration: | i.v.; daily; for three consecutive days | Result: | Resulted in a statistically significant reduction in tumor growth. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|